One Factor Driving Gilead Sciences (GILD) Stock Up to a One-Year High Today

NEW YORK (TheStreet) -- Gilead Sciences  (GILD) hit a new 52-week high of $107.40 as of 11:07 a.m. on Monday.

The biotech sector rose Monday after Swiss-based company Roche agreed to buy InterMune ITMN for $8.3 billion in an all-cash deal. The news sent several biotech stocks, including Gilead, Regeneron REGN and Celgene CELG, higher in morning trading.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

GILD Chart GILD data by YCharts

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he and Stephanie Link think could be potentially HUGE winners. Click here to see the holdings for FREE.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

If you liked this article you might like

These Stocks Pay You to Own Them

Don't Get Shaken Out of Good Stocks: Cramer's 'Mad Money' Recap (Wed 9/13/17)

Juno, bluebird In Focus as Targets Following Gilead-Kite Aquisition